Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Researchers Hope to Breathe New Life Into Immunotherapy for Prostate Cancer

October 13th 2016

Since the auspicious 2010 FDA approval of sipuleucel-T as the first immunotherapy vaccine for cancer, advancement with immunotherapy has been slow in the field of prostate cancer.

Expert Discusses Bone-Targeted Agents and Other Developments in mCRPC

October 11th 2016

Przemyslaw W. Twardowski, MD, describes the available therapies for patients with advanced metastatic castration-resistant prostate cancer, including bone-targeted therapies; the work that still lies ahead with these treatments; and the challenges with finding biomarkers to help develop targeted agents.

Role of Chemotherapy Remains Strong in High-Risk Localized Prostate Cancer

October 11th 2016

Howard M. Sandler, MD, sheds light on maximizing outcomes for patients with locally advanced prostate cancer, the evolving role of chemotherapy, and the steps to take once disease turns metastatic.

Minimal Toxicities Reported in Extreme Hypofractionated Comparison Trial in Prostate Cancer

October 10th 2016

Men with intermediate prostate cancer who received extreme hypofractionated radiotherapy reported a low incidence of side effects, with no significant differences compared with a similar cohort of men who received conventional fractionation after 2 years of treatment.

No Benefit Observed From Combined Irradiation in Intermediate-Risk Prostate Cancer

October 7th 2016

The addition of external-beam radiotherapy to interstitial brachytherapy failed to reduce prostate cancer progression compared to brachytherapy alone in men with intermediate-risk disease.

Dr. Zhang on Therapeutic Advancements in Prostate Cancer

October 7th 2016

Jingsong Zhang, MD, PhD, discusses the advancements for patients with metastatic castration-resistant prostate cancer (mCRPC) that have occurred over the last decade.

Dr. Dorff on Role of Chemotherapy in mCRPC

October 6th 2016

Tanya Dorff, MD, assistant professor of Clinical Medicine, Keck Medicine of University of Southern California, discusses the role of chemotherapy in patients with metastatic castration-resistant prostate cancer and pivotal clinical trials that have explored this.

H-RT Reduces Treatment Time by One-Third in Low-Risk Prostate Cancer

October 5th 2016

Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.

Dr. Micallef on NuQ Blood Tests in Prostate Cancer

October 5th 2016

Jake Micallef, PhD, chief scientific officer, VolitionRX, discusses the science of the NuQ biomarker assay as a detection tool for early-stage prostate cancer.

Stereotactic Radiation Potential Emerges in Prostate Cancer

September 28th 2016

Stereotactic ablative radiosurgery, which is administered in far fewer but larger doses than conventional radiotherapy, has the potential to benefit a substantial proportion of patients with low-, intermediate-, and potentially even high-risk prostate cancers.

Similar Survival Rates Reported Across Treatment Options for Localized Prostate Cancer

September 21st 2016

Treatment options for men with localized prostate cancer include active surveillance, radical prostatectomy, or external-beam radiotherapy, but in the Prostate Testing for Cancer and Treatment trial each therapy was associated with a low prostate-specific mortality rate of about 1%.

QOL in Men Undergoing Monitoring for Prostate Cancer Similar to Men With No Disease

September 19th 2016

Men with positive needle biopsy for prostate cancer who underwent active surveillance exhibited no difference in quality-of-life compared with men who had a negative prostate needle biopsy.

Biology of Bone Metastases in Patients With mCRPC

September 19th 2016

Conor Lynch, PhD, an associate professor of Tumor Biology at Moffitt Cancer Center, discusses the biology of bone metastases in patients with castration-resistant prostate cancer.

Study Addresses Appropriate Clinical Use of PSA Trial Data in Prostate Cancer

September 19th 2016

A treatment recommendation based on reduced prostate-specific antigen failure observed from early results of randomized controlled trials is not likely to prolong survival in men with moderate-to-severe comorbidities.

Dr. Luke Nordquist on the Impact of Additional Doses of Radium-223 in mCRPC

September 17th 2016

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a prospective study looking at the impact of an additional 6 doses of radium-223 dichloride in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.

Dr. Liauw on RT Advancements in Prostate Cancer

September 15th 2016

Stanley Liauw, MD, associate professor at the University of Chicago Medicine, discusses the advancements in radiation therapy (RT) over the last several years, and how he has seen the treatment affect his patients.

Exploring the "Dark Matter" in Prostate Cancer Genomics

September 14th 2016

Mark A. Rubin, MD, is an expert in prostate cancer genomics and pathology who has led key discoveries in the distinction between indolent and aggressive types of the malignancy.

Genomic Differences in Prostate Cancer Stages Are Coming Into Focus

September 13th 2016

Prostate cancer is slow-growing and readily curable in many cases, but the propensity for some tumors to develop into an aggressive, metastatic form that becomes resistant to androgen-targeting therapies continues to present a significant obstacle.

Expert Urges Revisiting PSA Screening After Pivotal Trial Update

September 13th 2016

After updated findings from the landmark Prostate, Lung, Colorectal, and Ovary screening trial were presented earlier this year, members of the oncology community strongly suggested that the United States Preventative Services Task Force revise its views on prostate-specific antigen screening for patients with prostate cancer.

Effects of Testosterone-Lowering Drugs in Patients With Prostate Cancer

September 13th 2016

Heather S. Jim, PhD, associate member in the Health Outcomes and Behavioral Department, Moffitt Cancer Center, discusses the effects of testosterone-lowering drugs used as a treatment for patients with prostate cancer.